THE NUMBER OF SHARES AND VOTES IN XBRANE HAS CHANGED AS A RESULT OF THE PREVIOUSLY ANNOUNCED REVERSE SPLIT OF 1:125.

Nyheter Xbrane Biopharma Nyheter alla bolag

Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här

Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

THE NUMBER OF SHARES AND VOTES IN XBRANE HAS CHANGED AS A RESULT OF THE PREVIOUSLY ANNOUNCED REVERSE SPLIT OF 1:125.

LHFI

At the extraordinary general meeting of Xbrane Biopharma AB (“Xbrane” or “the Company”) on October 13, 2025, it was resolved to consolidate shares at a ratio of 1:125, whereby 125 existing shares were combined into 1 new share. As of October 31, the number of shares and votes after the consolidation amounts to 20,605,348.

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

Datum	2025-11-03, kl 08:35
Källa	MFN

Bifogade filer

THE NUMBER OF SHARES AND VOTES IN XBRANE HAS CHANGED AS A RESULT OF THE PREVIOUSLY ANNOUNCED REVERSE SPLIT OF 1:125.

LOGGA IN

Xbrane Biopharma

Affiliate

THE NUMBER OF SHARES AND VOTES IN XBRANE HAS CHANGED AS A RESULT OF THE PREVIOUSLY ANNOUNCED REVERSE SPLIT OF 1:125.